Profile data is unavailable for this security.
About the company
Nanjing Medlander Medical Technology Co Ltd is a China-based company mainly engaged in the research and development, manufacture and sales of medical devices in pelvic floor and obstetrics and gynecology rehabilitation fields. The Company's products mainly include pelvic floor and obstetrics and gynecology rehabilitation product lines, reproductive rehabilitation and anti-aging product lines, sports rehabilitation product lines, consumables and information product lines and others. Its products include biostimulation feedback instrument, pelvic training instrument, pelvic biostimulation feedback instrument, vaginal electrode, pelvic care instrument and others. The Company's products are mainly applied in medical institutions' obstetrics and gynecology, gynecology, pelvic floor rehabilitation centers, as well as professional institutions such as confinement centers, postpartum recovery centers and mother-child centers. The Company mainly distributes its products within domestic market.
- Revenue in CNY (TTM)380.95m
- Net income in CNY101.15m
- Incorporated2013
- Employees481.00
- LocationNanjing Medlander Medical Technology Co LtdNanjing 210012ChinaCHN
- Phone+86 2 569782957
- Fax+86 2 569782957
- Websitehttps://www.medlander.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allgens Medical Technology Co Ltd | 191.19m | 5.11m | 2.28bn | 202.00 | 483.35 | 1.61 | -- | 11.94 | 0.0348 | 0.0348 | 1.45 | 10.49 | 0.1251 | 1.32 | 2.81 | 946,490.30 | 0.0232 | 7.62 | 0.0241 | 8.30 | 73.87 | 83.60 | 0.1855 | 39.05 | 24.27 | -- | 0.0333 | 5.25 | -7.68 | 12.86 | -43.04 | 10.46 | -26.12 | -- |
| Jiangsu Cowin Biotech Co Ltd | 118.17m | -144.51m | 2.47bn | 657.00 | -- | 1.61 | -- | 20.94 | -1.30 | -1.30 | 1.06 | 13.63 | 0.0667 | 1.32 | 1.43 | 179,863.40 | -8.45 | -- | -8.93 | -- | 53.54 | -- | -126.60 | -- | 13.60 | -- | 0.0214 | -- | -67.15 | -- | -153.00 | -- | -- | -- |
| Nanjing Medlander Medical Tech Co Ltd | 380.95m | 101.15m | 2.55bn | 481.00 | 24.92 | 1.95 | -- | 6.70 | 1.02 | 1.02 | 3.86 | 13.10 | 0.2527 | 1.98 | 21.47 | 791,989.40 | 7.06 | -- | 7.76 | -- | 71.46 | -- | 27.94 | -- | 7.57 | -- | 0.0115 | -- | -9.57 | -- | -26.19 | -- | -- | -- |
| Chemclin Diagnostics Co Ltd | 443.86m | 139.29m | 2.85bn | 731.00 | 20.45 | 2.04 | -- | 6.43 | 0.3476 | 0.3476 | 1.11 | 3.49 | 0.2491 | 1.00 | 16.34 | 607,195.30 | 7.82 | 11.01 | 8.73 | 12.32 | 74.89 | 74.19 | 31.38 | 31.07 | 5.16 | -- | 0.1515 | 36.64 | -4.28 | 4.00 | -3.44 | -- | 44.10 | -- |
| Cowealth Medical China Co Ltd | 970.41m | 29.67m | 2.90bn | 240.00 | 97.69 | 2.48 | -- | 2.99 | 0.0745 | 0.0745 | 2.44 | 2.93 | 0.6435 | 3.90 | 1.25 | 4,043,355.00 | 2.01 | 5.80 | 2.59 | 8.09 | 19.62 | 20.74 | 3.13 | 6.14 | 3.65 | -- | 0.0829 | 23.89 | -14.62 | 3.85 | -42.96 | -6.75 | 32.85 | -- |
| Nanjing Vishee Medical Technology Co Ltd | 422.21m | 112.74m | 2.90bn | 700.00 | 25.64 | 1.80 | -- | 6.87 | 1.18 | 1.18 | 4.42 | 16.83 | 0.2401 | 3.12 | 12.37 | 603,153.40 | 6.41 | 10.27 | 6.92 | 11.43 | 70.21 | 73.26 | 26.70 | 33.99 | 8.31 | -- | 0.0003 | 47.57 | 43.72 | 17.34 | 45.22 | 16.55 | 26.69 | -- |
| Beijing Succeeder Technology Inc | 297.74m | 112.75m | 2.94bn | 296.00 | 26.10 | 1.80 | -- | 9.86 | 1.06 | 1.06 | 2.80 | 15.41 | 0.1766 | 2.51 | 8.66 | 1,005,870.00 | 6.69 | 7.77 | 7.02 | 8.25 | 60.39 | 61.03 | 37.85 | 38.34 | 14.78 | -- | 0.00004 | 22.22 | 20.40 | 6.60 | 12.29 | 15.57 | 99.03 | -- |
| Beijing Hotgen Biotech Co Ltd | 520.50m | -67.64m | 2.98bn | 1.04k | -- | 0.9132 | -- | 5.72 | -0.7349 | -0.7349 | 5.74 | 35.25 | 0.1484 | 2.20 | 5.85 | 502,410.60 | -2.13 | 29.65 | -2.22 | 34.70 | 46.98 | 56.08 | -14.33 | 32.26 | 8.95 | -- | 0.0026 | 41.92 | -84.78 | 23.67 | -97.10 | -10.67 | 57.98 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Rongtong Fund Management Co., Ltd.as of 30 Jun 2024 | 4.62m | 19.50% |
| Golden Trust Sinopac Fund Management Co., Ltd.as of 30 Jun 2024 | 450.46k | 1.90% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 255.21k | 1.08% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 244.37k | 1.03% |
| Orient Securities Asset Management Co. Ltd.as of 30 Jun 2024 | 129.52k | 0.55% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 107.30k | 0.45% |
| Dongxing Asset Management Co. Ltd.as of 30 Jun 2024 | 89.21k | 0.38% |
| CCB Principal Asset Management Co., Ltd.as of 30 Jun 2024 | 51.85k | 0.22% |
| China Fund Management Co., Ltd.as of 30 Jun 2024 | 40.62k | 0.17% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2024 | 40.30k | 0.17% |
